TABLE 2
FROM:
Histologic and immunohistochemical decision-making in endometrial adenocarcinoma
Lesley Lomo, Marisa R Nucci, Kenneth R Lee, Ming-Chieh Lin, Michelle S Hirsch, Christopher P Crum and George L Mutter
BACK TO ARTICLETable 2. Diagnostic concordance and p53 outcomes by diagnostic schema
| Schema | Class | Agreement | N (% of Type I/Type II) | P53-positive |
|---|---|---|---|---|
| Classic (2-class) | Type I, n=63 | 2/3 | 10/63 (16%) | 7/10 (70%) |
| 3/3 | 53/63 (84%) | 8/53 (15%) | ||
| Type II, n=40 | 2/3 | 11/40 (28%) | 8/11 (73%) | |
| 3/3 | 29/40 (72%) | 25/29 (86%) | ||
| Expanded (3-class) | Type I, n=65 | 1/3 | 14/65 (22%) | 12/14 (86%) |
| 2/3 | 13/65 (20%) | 4/13 (31%) | ||
| 3/3 | 38/65 (58%) | 1/38 (3%) | ||
| Uncertain, n=44 | 1/3 | 29/44 (66%) | 16/30 (53%) | |
| 2/3 | 13/44 (30%) | 11/13 (85%) | ||
| 3/3 | 2/44 (4%) | 2/2 (100%) | ||
| Type II, n=42 | 1/3 | 7/42 (15%) | 4/7 (57%) | |
| 2/3 | 19/42 (45%) | 15/19 (79%) | ||
| 3/3 | 16/42 (38%) | 14/16 (88%) |
